Lee Sun Hee, Shin Dong-Soo, Kim Jong Ran, Kim Hyunjung
Department of Nursing, Hallym University Sacred Heart Hospital, 22 Gwanpyeong-ro 170 beon-gil, Anyang-si, Gyeonggi-do, 14068, South Korea.
Division of Nursing, Research Institute of Nursing Science, Hallym University, 1 Hallymdaehak-gil, Chuncheon, Gangwon-do, 24252, South Korea.
Heart Lung. 2017 May-Jun;46(3):137-142. doi: 10.1016/j.hrtlng.2017.02.003. Epub 2017 Mar 16.
To identify factors associated with mortality in patients treated with veno-arterial extracorporeal membrane oxygenation (VA-ECMO) and to validate the discrimination of the risk assessment tools to predict mortality.
VA-ECMO is a rescue therapy for patients with life-threatening cardiac failure, but mortality remains high.
In this retrospective study, we reviewed the medical records of adult patients who underwent VA-ECMO in an intensive care unit of a university hospital, between 2009 and 2013.
VA-ECMO was performed in 89 patients, with a median duration of 116 h. The survival rate until hospital discharge was 27%. The pre-ECMO simplified acute physiology score (SAPS) II and diabetes mellitus were significant predictors of hospital mortality. The optimal prognostic SAPS II score was 81 overall, 80 in patients with diabetes, and 84 in those without diabetes.
Our findings indicate that high pre-ECMO SAPS II score and diabetes are risk factors for mortality in patients who undergo VA-ECMO.
确定接受静脉-动脉体外膜肺氧合（VA-ECMO）治疗患者的死亡相关因素，并验证预测死亡风险评估工具的判别能力。
VA-ECMO是一种用于治疗危及生命的心力衰竭患者的挽救疗法，但死亡率仍然很高。
在这项回顾性研究中，我们查阅了2009年至2013年期间在一所大学医院重症监护病房接受VA-ECMO治疗的成年患者的病历。
89例患者接受了VA-ECMO治疗，中位持续时间为116小时。出院生存率为27%。体外膜肺氧合前简化急性生理学评分（SAPS）II和糖尿病是医院死亡率的显著预测因素。预测预后的最佳SAPS II评分为总体81分，糖尿病患者为80分，非糖尿病患者为84分。
我们的研究结果表明，体外膜肺氧合前SAPS II评分高和糖尿病是接受VA-ECMO治疗患者死亡的危险因素。
